Edgewise Therapeutics: More Expensive Now, But Much More Derisked
Source: SeekingAlpha
2025-03-10 13:36:32 ET
Summary
- Edgewise Therapeutics' stock surged after strong midstage data from its Becker Muscular Dystrophy program, with the lead molecule sevasemten showing promising results.
- The GRAND CANYON trial, targeting Becker Muscular Dystrophy, aims for regulatory approval with primary endpoint NSAA, following positive Phase 2 CANYON data.
- Financially, Edgewise has a market cap of $2.67bn and a cash runway of 8-9 quarters, supporting ongoing and future trials.
- Despite the increased stock price, EWTX remains a buy due to its derisked status and potential success across multiple myosin inhibition programs.
...
Read the full article on Seeking Alpha
For further details see:
Edgewise Therapeutics: More Expensive Now, But Much More Derisked
Edgewise Therapeutics Inc.
NASDAQ: EWTX
EWTX Trading
-3.24% G/L:
$37.79 Last:
651,556 Volume:
$40 Open:
EWTX Latest News
June 01, 2026 08:30:00 am
Edgewise Therapeutics Announces Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline
EWTX Stock Data
$3,280,862,770
54,628,112
N/A
52
N/A
Biotechnology & Life Sciences
Healthcare
US
Boulder
